Acta Neuropathologica

, Volume 108, Issue 1, pp 49–56

Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas

  • Yoshikazu Okamoto
  • Pier-Luigi Di Patre
  • Christoph Burkhard
  • Sonja Horstmann
  • Benjamin Jourde
  • Michael Fahey
  • Danielle Schüler
  • Nicole M. Probst-Hensch
  • M. Gazi Yasargil
  • Yasuhiro Yonekawa
  • Urs M. Lütolf
  • Paul Kleihues
  • Hiroko Ohgaki
Regular Paper

Abstract

We carried out a population-based study on low-grade diffuse gliomas in the Canton of Zurich, Switzerland (population 1.16 million). From 1980 to 1994, 987 astrocytic and oligodendroglial tumors were diagnosed, of which 122 (12.4%) were low-grade (WHO grade II). The incidence rates adjusted to the World Standard Population, per million population per year, were 2.28 for low-grade diffuse astrocytomas, 0.89 for oligoastrocytomas, and 2.45 for oligodendrogliomas. The survival rate (mean follow-up 7.5±4.8 years) was highest for patients with oligodendroglioma (78% at 5 years, 51% at 10 years), followed by those with oligoastrocytoma (70% at 5 years, 49% at 10 years) and fibrillary astrocytoma (65% at 5 years, 31% at 10 years). Survival of patients with gemistocytic astrocytoma was poor, with survival rates of 16% at 5 years and 0% at 10 years. Younger patients (<50 years) survived significantly longer than older patients (>50 years; P=0.013). DNA sequencing, performed in 84% of cases, revealed that TP53 mutations were most frequent in gemistocytic astrocytomas (88%), followed by fibrillary astrocytomas (53%) and oligoastrocytomas (44%), but were infrequent (13%) in oligodendrogliomas. The presence of TP53 mutations was associated with shorter survival of patients with low-grade diffuse gliomas (log-rank test; P=0.047), but when each histological type was analyzed separately, an association was observed only for oligoastrocytoma (P=0.05). Loss on 1p and 19q were assessed by quantitative microsatellite analysis in 67% of cases. These alterations were frequent in oligodendrogliomas (1p, 57%; 19q, 69%), less common in oligoastrocytomas (1p, 27%; 19q, 45%), rare in fibrillary astrocytomas (1p, 7%; 19q, 7%), and absent in gemistocytic astrocytomas. None of these alterations were predictive of survival. These results establish the frequency of key genetic alterations in low-grade diffuse gliomas at a population-based level. Multivariate Cox’s regression analysis indicates that only age and histological type, but not genetic alterations, are significant predictive factors.

Keywords

Low-grade diffuse astrocytoma Oligodendroglioma Oligoastrocytoma Population-based study Survival Incidence rate 

References

  1. 1.
    Central Brain Tumor Registry of the United States (CBTRUS; http://www.cbtrus.org) 2002Google Scholar
  2. 2.
    Al Sarraj S, Bridges LR (1995) p53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg 9:143–149PubMedGoogle Scholar
  3. 3.
    Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG (2000) Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 48:825–830PubMedGoogle Scholar
  4. 4.
    Buckner JC, Gesme D, Jr., O’Fallon JR, Hammack JE, Staffod S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R (2003) Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251–255CrossRefPubMedGoogle Scholar
  5. 5.
    Burkhard C, Patre PL di, Schüler D, Ysargil MG, Lütolf U, Kleihues P, Ohgaki H (2003) A population-based study on the incidence and survival of patients with pilocytic astrocytoma. J Neurosurg 98:1170–1174PubMedGoogle Scholar
  6. 6.
    Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479PubMedGoogle Scholar
  7. 7.
    Chozick BS, Pezzullo JC, Epstein MH, Finch PW (1994) Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35:831–837PubMedGoogle Scholar
  8. 8.
    Henderson KH, Shaw EG (2001) Randomized trials of radiation therapy in adult low-grade gliomas. Semin Radiat Oncol 11:145–151CrossRefPubMedGoogle Scholar
  9. 9.
    Hilton DA, Love S, Barber R, Ellison D, Sandeman DR (1998) Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery 42:724–729PubMedGoogle Scholar
  10. 10.
    Iuzzolino P, Ghimenton C, Nicolato A, Giorgiutti F, Fina P, Doglioni C, Barbareschi M (1994) p53 protein in low-grade astrocytomas: a study with long-term follow-up. Br J Cancer 69:586–591PubMedGoogle Scholar
  11. 11.
    Kleihues P, Cavenee WK (eds) (2000) World Health Organization Classification of Tumours: pathology and genetics of tumours of the nervous system. IARC Press, LyonGoogle Scholar
  12. 12.
    Kleihues P, Davis RL, Ohgaki H, Burger PC, Westphal MM, Cavenee WK (2000) Diffuse astrocytoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, pp 22–26Google Scholar
  13. 13.
    Kraus JA, Bolln C, Wolf HK, Neumann J, Kindermann D, Fimmers R, Forster F, Baumann A, Schlegel U (1994) TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer 10:143–149PubMedGoogle Scholar
  14. 14.
    Krouwer HG, Davis RL, Silver P, Prados M (1991) Gemistocytic astrocytomas: a reappraisal. J Neurosurg 74:399–406PubMedGoogle Scholar
  15. 15.
    Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, Deimling A von (1997) Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56:1098–1104Google Scholar
  16. 16.
    Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter hypermethylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C — A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22:1715–1719PubMedGoogle Scholar
  17. 17.
    Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 59:539–543PubMedGoogle Scholar
  18. 18.
    Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158:1253–1262PubMedGoogle Scholar
  19. 19.
    Ohgaki H, Vital A, Kleihues P, Hainaut P (2000) Li-Fraumeni syndrome and TP53 germline mutations. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, pp 231–234Google Scholar
  20. 20.
    Ohshima H, Bartsch H (1994) Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 305:253–264PubMedGoogle Scholar
  21. 21.
    Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ (2002) Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8:1117–1124PubMedGoogle Scholar
  22. 22.
    Pignatti F, van den BM, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084CrossRefPubMedGoogle Scholar
  23. 23.
    Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324–1330PubMedGoogle Scholar
  24. 24.
    Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP (2000) Oligoastrocytoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, pp 65–67Google Scholar
  25. 25.
    Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP (2000) Oligodendroglioma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, pp 56–61Google Scholar
  26. 26.
    Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126Google Scholar
  27. 27.
    Reis RM, Hara A, Kleihues P, Ohgaki H (2001) Genetic evidence of the neoplastic nature of gemistocytes in astrocytomas. Acta Neuropathol 102:422–425PubMedGoogle Scholar
  28. 28.
    Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, Louis DN (2002) Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade “oligodendroglioma”. J Neuropathol Exp Neurol 61:58–63PubMedGoogle Scholar
  29. 29.
    Schlegel U (1994) p53: an important or most overvalued tumor gene? Laryngol Rhinol Otol 73:651–653Google Scholar
  30. 30.
    Shaw EG, Wisoff JH (2003) Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro-oncol 5:153–160Google Scholar
  31. 31.
    Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMedGoogle Scholar
  32. 32.
    Streffer J, Schabet M, Bamberg M, Grote EH, Meyermann R, Voigt K, Dichgans J, Weller M (2000) A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurol 247:297–302PubMedGoogle Scholar
  33. 33.
    van der Bent MJ, Kros JM, Heimans JJ, Pronk LC, Van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology 51:1140–1145PubMedGoogle Scholar
  34. 34.
    Wallner KE, Gonzales M, Sheline GE (1988) Treatment of oligodendrogliomas with or without postoperative irradiation. J Neurosurg 68:684–688PubMedGoogle Scholar
  35. 35.
    Watanabe K, Peraud A, Gratas C, Wakai S, Kleihues P, Ohgaki H (1998) p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol 95:559–564CrossRefPubMedGoogle Scholar
  36. 36.
    Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217–224PubMedGoogle Scholar
  37. 37.
    Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H (1997) Role of gemistocytes in astrocytoma progression. Lab Invest 76:277–284PubMedGoogle Scholar
  38. 38.
    Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H (2001) Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 103:267–275PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Yoshikazu Okamoto
    • 1
  • Pier-Luigi Di Patre
    • 1
  • Christoph Burkhard
    • 1
  • Sonja Horstmann
    • 1
  • Benjamin Jourde
    • 1
  • Michael Fahey
    • 1
  • Danielle Schüler
    • 2
  • Nicole M. Probst-Hensch
    • 2
  • M. Gazi Yasargil
    • 3
  • Yasuhiro Yonekawa
    • 4
  • Urs M. Lütolf
    • 5
  • Paul Kleihues
    • 1
  • Hiroko Ohgaki
    • 1
  1. 1.International Agency for Research on CancerLyon Cedex 08France
  2. 2.Cancer RegistryCanton of ZurichZurichSwitzerland
  3. 3.Department of NeurosurgeryCollege of MedicineLittle RockUSA
  4. 4.Department of NeurosurgeryUniversity Hospital ZurichZurichSwitzerland
  5. 5.Department of RadiologyUniversity Hospital ZurichZurichSwitzerland

Personalised recommendations